Business
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel ...
About this update from Bioinvent International Ab
[{"type":"text","content":"BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million","length":108,"tagName":"p"},{"type":"text","content":"LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it has reached a development milestone under a license agreement related to HMI-115, an anti-prolactin receptor antibody targeting moderate to severe endometriosis-associated pain. The achievement follows the initiation of a Phase 3 clinical trial for HMI‑115 by Hope Medicine (Nanjing) Co. Ltd. ("Hope Medicince").","length":533,"tagName":"p"},{"type":"text","content":"The Phase 3 trial (NCT07318688) is a randomized, multicenter, double‑blind, placebo‑controlled trial designed to assess the efficacy and safety of HMI‑115 over a 24‑week treatment period, followed by a 28‑week extension. The trial is sponsored by Hope Medicine and is expected to enroll approximately 540 pre-menopausal women across sites in Beijing, Jiangsu, Shanghai, and Tianjin, China.","length":389,"tagName":"p"},{"type":"text","content":"HMI‑115 was discovered using BioInvent's proprietary n‑CoDeR® phage display technology under a 2008 collaboration agreement with Bayer. The program was subsequently assigned to Hope Medicine in 2019. BioInvent is now entitled to a milestone payment of €1 million. This milestone represents the continued validation of BioInvent's ability to generate high-potential therapeutic candidates that progress through global clinical pipelines.","length":444,"tagName":"p"},{"type":"text","content":"HMI-115 is one of several therapeutic antibodies discovered through BioInvent's proprietary n-CoDeR and F.I.R.S.T screening platforms that are currently being advanced by our global collaborators. With three out-licensed candidates now in clinical development, BioInvent remains positioned to capture significant value through ongoing development milestones and future royalties on potential sales.","length":402,"tagName":"p"},{"type":"text","content":"About BioInvent","length":15,"tagName":"p"},{"type":"text","content":"BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immu...